All manuscripts
Publications CAR T Cells G-Rex®100M

A SUPPLY CHAIN CRISIS STORY: CULTURE BAG SHORTAGE ENFORCED VALIDATION OF AN ALTERNATIVE EXPANSION SYSTEM FOR CAR T CELLS

Published Journal Cytotherapy

Share
1 page A SUPPLY CHAIN CRISIS STORY: CULTURE BAG SHORTAGE ENFORCED VALIDATION OF AN ALTERNATIVE EXPANSION SYSTEM FOR CAR T CELLS — Cytotherapy, 2022

Overview

Due to supply chain shortages, the authors validated G-Rex® vessels as an alternative to Wave bioreactors for CAR T expansion. G-Rex® 1L vessels produced 2-4 billion T cells with >90% viability and comparable phenotype/function, using significantly less media and labor than the Wave system.

What this paper found

G-Rex® vessels were validated as a replacement for Wave bioreactor culture bags to manufacture lentiviral CAR T cells when bag supply ran short. Mesothelin CAR T cells from consented patient material were produced in parallel in G-Rex® and Wave systems. G-Rex® products showed lower transduction efficiency at the same multiplicity of infection, yet expansion was at least 50-fold, viability exceeded 90%, and phenotypes were comparable. Cells from both processes mediated CAR-dependent cytotoxicity and cytokine production. A 1 L G-Rex® seeded with 50 million T cells yielded 2-4 billion cells, using one third of the starting material and one fifth of the media needed in the Wave, with less manual effort.

Notably, this process required just 1/3 of the starting material, 1/5 of the media and decreased manual effort through culture duration compared to the Wave. — M. Gohil, D. Hasenmayer, K. M. Haines, A. Jain, L. Lewitt, K. Sporici, A. Dai, D. Negorev, V. E. Gonzalez, I. Kulikovskaya, R. Reynolds, T. Migliaccio, A. L. Brennan, T. A. Colligon, A. L. Russell, Z. Wang, C. June, D. Siegel, B. L. Levine, J. A. Fraietta, J. Jadlowsky, G. Plesa, M. M. Davis, Cytotherapy

Study details

Authors
M. Gohil, D. Hasenmayer, K. M. Haines, A. Jain, L. Lewitt, K. Sporici, A. Dai, D. Negorev, V. E. Gonzalez, I. Kulikovskaya, R. Reynolds, T. Migliaccio, A. L. Brennan, T. A. Colligon, A. L. Russell, Z. Wang, C. June, D. Siegel, B. L. Levine, J. A. Fraietta, J. Jadlowsky, G. Plesa, M. M. Davis
Institution
Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States
Journal
Cytotherapy
Year
2022
G-Rex® model(s)
G-Rex®100M
Cell type(s)
CAR T Cells
Application area
Solid tumor
Study phase
Preclinical

How G-Rex® was used

Mesothelin CAR T cells were produced from consented patient starting material in disposable G-Rex® culture vessels, in parallel with the conventional Wave bioreactor, within a closed-system lentiviral CAR T manufacturing platform. In the 1L G-Rex®, a seed of 50 million T cells yielded 2-4 billion T cells, with at least 50-fold expansion and viability above 90%.

Explore related

Full citation

Gohil M, Hasenmayer D, Haines KM, et al. A supply chain crisis story: culture bag shortage enforced validation of an alternative expansion system for CAR T cells. Cytotherapy. 2022;24:S160.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →